Today's Daily Dose brings you news about the FDA decisions related to Biohaven's NURTEC and Celgene's OTEZLA; interim data from Marker's MultiTAA T cell therapy trial and Takeda's phase III trial results of subcutaneous formulation of Vedolizumab in Crohn's disease, among others.
from RTT - Biotech https://ift.tt/2ZdQs8d
via IFTTT
No comments:
Post a Comment